


SAINT LUKE'S MID AMERICA HEART INSTITUTE

2020



KANSAS CITY,
MISSOURI

 **Saint Luke's**
MID AMERICA HEART INSTITUTE

**BEST
HOSPITALS**
& WORLD REPORT
U.S. News
NATIONAL
CARDIOLOGY &
HEART SURGERY
2019-20

SAINT LUKE'S MID AMERICA HEART INSTITUTE

2020

 Saint Luke's™
MID AMERICA HEART INSTITUTE





Comprehensive Cardiac Center Certification



Advanced Heart Failure Certification



Cardiac Valve Repair and Replacement Certification



Advanced Ventricular Assist Device Certification



Acute Myocardial Infarction Certification



One of 75 hospitals in the world to earn Magnet Designation four consecutive years



MICHAEL MAIN, MD
Co-Executive Medical Director;
Professor of Medicine, UMKC



A. MICHAEL BORKON, MD
Co-Executive Surgical Director;
Clinical Professor of Surgery,
UMKC

Dear Colleagues,

In 1981, Saint Luke’s Mid America Heart Institute (MAHI) opened the doors to the world’s first dedicated, free-standing heart institute, focused specifically on caring for patients with cardiovascular disease. Since that time, our reputation for clinical excellence and innovation has grown across the nation. At Saint Luke’s, we continue to offer patient treatment options that are only available at a few institutions in this country. With these objectives, we have created the largest, most vibrant, cardiac program in the region.

Gone is the day when the knowledge of cardiovascular medicine is contained within a handful of books. Advances in our field continue at an impressive speed. Every year, we gain more insight to cardiac pathology and offer new treatment options. We know that critically ill patients realize better clinical outcomes if they are cared for at high-volume centers with board-certified sub-specialists within every field of cardiovascular medicine and surgery. More importantly, we have fostered an environment whereby collaboration and multi-disciplinary discussion are the norm. Our focus on quality is not just for the hospitalized patient. We are equally committed to disease prevention and wellness, so that our patients can remain healthy and active.

The Saint Luke’s Mid America Heart Institute mission extends beyond excellence in patient care. We are deeply committed to cardiovascular research and training the next generation of exceptional cardiologists. We are proud of the accolades listed throughout this book, a reflection of our work at Saint Luke’s.

To our community, patients, and referring physicians, we are honored to be trusted with your cardiovascular care.

Sincerely,

Michael Main, MD
Co-Executive Medical Director

A. Michael Borkon, MD
Co-Executive Surgical Director



NOTABLE RECOGNITIONS

CLINICAL EXCELLENCE

- One of the top 50 in the nation for cardiology and heart surgery as ranked by *U.S. News and World Report*
- Third hospital in the United States to receive Comprehensive Cardiac Certification from The Joint Commission
- First hospital in the region to receive Cardiac Valve Repair and Replacement Certification from The Joint Commission
- Best cardiac transplant outcomes in the nation, according to Scientific Registry of Transplant Recipients

RESEARCH AND EDUCATION

- Published more than 1,000 peer-reviewed articles in the past five years
- Actively involved in more than 100 clinical trials
- In addition to a three-year cardiology training program jointly offered by Saint Luke's Mid America Heart Institute and the University of Missouri–Kansas City School of Medicine, we support subspecialty education in the fields of electrophysiology, interventional cardiology, advanced heart failure and cardiac transplantation, and structural heart disease
- Saint Luke's Mid America Heart Institute is also one of four U.S. centers to offer a two-year advanced fellowship in Outcomes Research, funded by the National Institutes of Health (NIH)
- \$7.5 million in research funding in 2018
- Many cardiologists at Saint Luke's Mid America Heart Institute are professors or associate professors at the University of Missouri–Kansas City (UMKC) School of Medicine, Kansas City, Missouri



NATIONAL LEADERSHIP POSITIONS HELD BY SAINT LUKE'S MID AMERICA HEART INSTITUTE PHYSICIANS

- American Heart Association Social Determinants of Cardiovascular Care, Chair – Paul S. Chan, MD
- American Society of Echocardiography, Board of Directors – Michael L. Main, MD
- American College of Cardiology Coding Task Force, Chair; American College of Nuclear Cardiology, Vice President – Randall C. Thompson, MD
- Diabetes Collaborative Registry Steering Committee (American College of Cardiology, American Diabetes Association, American College of Physicians, Joslyn Diabetes Center, American Association of Clinical Endocrinologists), Chair – Mikhail N. Kosiborod, MD
- Food and Drug Administration, Circulatory System Devices Panel, Member – Keith B. Allen, MD

NATIONAL AND INTERNATIONAL HONORS RECEIVED BY SAINT LUKE'S MID AMERICA HEART INSTITUTE PHYSICIANS

- Transcatheter Cardiovascular Therapeutics Asia Pacific – Master of Masters in Interventional Cardiology 2016 – Barry D. Rutherford, MD
- American Heart Association, Distinguished Scientist – John A. Spertus, MD
- American Society of Nuclear Cardiology, Master – Timothy M. Bateman, MD
- Burgess Gordon Award – American Medical Association, 2019 – Randall C. Thompson, MD






TABLE OF CONTENTS

10	By the Numbers
11	Caring for Our Community
13	STATE-OF-THE-ART CARDIOVASCULAR MEDICINE
14	Advanced Heart Failure
15	Left Ventricular Assist Device
16	Extracorporeal Membrane Oxygenation
18	Cardiac Transplantation
20	Advanced Cardiac Imaging
23	Complex Coronary Artery Disease
24	Cardiac Surgery
26	Thoracic Surgery
27	Valvular Heart Disease
29	Electrophysiology
30	Left Atrial Appendage Closure
32	Peripheral Arterial Disease
32	Chronic Venous Disease
33	Adult Congenital Heart Disease
34	Heart Disease in Pregnancy
35	Cardiac Amyloid Clinic
37	PREVENTION
38	Muriel I. Kauffman Women's Heart Center
39	Charles & Barbara Duboc Cardio Health & Wellness Center
40	Michael & Marlys Haverty Cardio Metabolic Center of Excellence
41	Athletic Heart Clinic
43	CARDIOVASCULAR RESEARCH
44	Outcomes Research
45	The World's Most Influential Scientific Mind
46	Diabetes Research
47	EDUCATION AND FELLOWSHIP TRAINING PROGRAMS
48	Cardiovascular Disease Fellowship
50	Dr. Robert D. Conn Heart Conference
51	MEET THE TEAM
61	DONORS





SAINT LUKE'S MID AMERICA HEART INSTITUTE



Dr. Borkon helps a young girl listen to her dad's heart, donated to Jamie Poindexter, a heart transplant recipient.

OUR PATIENTS

2018 VOLUMES

80,000

OUTPATIENT

26,000

INPATIENT

OUR TEAM

63

CARDIOLOGISTS

46

CARDIAC ADVANCED PRACTICE
PROVIDERS

9

CARDIOTHORACIC /VASCULAR
SURGEONS

23

CARDIOTHORACIC ADVANCED
PRACTICE PROVIDERS

13


CARDIAC ANESTHESIOLOGISTS/
CRITICAL CARE INTENSIVISTS

14


CRITICAL CARE ADVANCED
PRACTICE PROVIDERS

CARING FOR OUR COMMUNITY

SAINT LUKE'S MID AMERICA HEART INSTITUTE LOCATIONS







STATE-OF-THE-ART CARDIOVASCULAR MEDICINE

ADVANCED HEART FAILURE



ANTHONY MAGALSKI, MD
Co-Medical Director,
Advanced Heart Failure
Professor of Medicine, UMKC




BETHANY AUSTIN, MD
Co-Medical Director,
Advanced Heart Failure;
Associate Professor of Medicine,
UMKC

Awarded by the American Heart Association and The Joint Commission with a Certification in Advanced Heart Failure, Saint Luke’s Mid America Heart Institute’s Heart Failure Program provides expert, comprehensive care for patients at all stages of the disease process, from prevention to the sophisticated care that critically ill patients demand.

Our program delivers high-quality, coordinated heart failure care to patients in the Kansas City metro and throughout Missouri, Kansas, Iowa, Arkansas, Oklahoma, Nebraska, and beyond. In recognition of our relentless efforts to offer patients the best care, we continue to receive national commendations:

- Highest level of recognition for heart failure care awarded by the American Heart Association/American Stroke Association: Heart Failure Gold Plus with Target: Heart Failure Honor Roll
- Heart Failure Honor Roll Quality Achievement Award for consistently implementing specific American Heart Association/American College of Cardiology Foundation recommended quality improvement measures

All-cause 30-day heart failure mortality is almost **2 percent lower** compared to the rest of the nation.



LEFT VENTRICULAR ASSIST DEVICE



SANJEEV AGGARWAL, MD
Surgical Director, Left Ventricular Assist Device Program;
Clinical Assistant Professor of Surgery, UMKC



MARK EVERLEY, MD
Medical Director, Left Ventricular Assist Device Program;
Assistant Professor of Medicine, UMKC

AWARDED THE JOINT COMMISSION CERTIFICATION

Saint Luke's Mid America Heart Institute has more experience in caring for critically ill heart patients than any other hospital in the region. For patients who need immediate life-saving advanced circulatory support due to severe heart failure and cannot wait for a heart transplant, a surgically implanted mechanical pump may be the only option. Evaluated by our multidisciplinary heart team, eligible patients can receive this lifesaving intervention. Left ventricular assist devices (LVADs) are used either for a bridge to transplant or for destination therapy in patients who are not transplant eligible.

In addition to LVADs, we have several options for temporary cardiac support devices for both the left and right ventricles, such as an intra-aortic blood pump, Impella®, Impella RP®, and Protek™.



Bethany Austin, MD, Heart Failure Cardiologist, with patient Melissa Wells, checking her LVAD battery that keeps Melissa's mechanical heart pumping.

KEVIN NUNNINK ECMO PROGRAM (EXTRACORPOREAL MEMBRANE OXYGENATION)



MICHELLE HAINES, MD
Director, Cardiovascular
ICU and ECMO

For the most critically ill patients who need emergent and total cardiopulmonary or respiratory support, extracorporeal membrane oxygenation (ECMO) may be the only option. Recognized for its expertise, Saint Luke's Mid America Heart Institute is a referral center for this challenging group of patients. The medical care of these profoundly ill patients is directed by a team of critical care intensivists, supported by the full complement of resources available at Saint Luke's.

- Since 2009, we have placed more than 100 patients with severe acute cardiac or respiratory failure on ECMO
- Our rate of survival exceeds the national average

In an era when the number of ECMO programs have more than doubled in the last decade, **Saint Luke's Mid America Heart Institute remains a leader.** In 2018, we were recognized by Extracorporeal Life Support Organization (ELSO) with the Gold Level ELSO Award for Excellence in Life Support.



TROY SYDZYIK
ECMO Coordinator and
Chief of Perfusion

ONLY ADULT ECMO PROGRAM RECOGNIZED FOR EXCELLENCE IN THE REGION



ONE PATIENT'S STORY

Cheyenne was otherwise healthy when she suddenly collapsed at work from ventricular fibrillation. After six minutes of CPR and four shocks with an automated external defibrillator, she finally regained a pulse. Due to critical cardiac and respiratory failure, she was immediately transferred to Saint Luke's. Cheyenne was placed on veno-venous ECMO as the only option to ensure adequate oxygenation.

Over the next seven days her pulmonary status normalized, and she was successfully weaned from ECMO support. Her episode of sudden cardiac arrest was due to long QT syndrome, a genetic condition known to cause fatal arrhythmias. She received a cardiac defibrillator and returned home completely recovered.



Cheyenne Mize, 24, former ECMO patient, with her husband Joe.

CARDIAC TRANSPLANTATION SINCE 1985



MICHAEL BORKON, MD
Surgical Director,
Cardiac Transplantation;
Clinical Professor of Surgery,
UMKC

With more than 800 heart transplants performed, Saint Luke’s ranks among the largest centers nationwide in volume. We also offer the region’s most experienced comprehensive cardiovascular care program—from prevention to transplantation—making Saint Luke’s Mid America Heart Institute the leader in cardiovascular care in the Midwest region. Using a multi-disciplinary approach in patient care, our highly skilled team continually exceeds quality benchmarks set by national transplant standards. The success of our transplant service is enhanced by the strength of advanced heart failure and ventricular assist device programs.


Saint Luke’s Mid America Heart Institute **ranks second in the nation**, out of 144 programs, in outcomes of patients referred for heart transplantation.

(according to Scientific Registry of Transplant Recipients)



ANDREW KAO, MD
Medical Director,
Cardiac Transplantation;
Professor of Medicine, UMKC


Committed to Kansas City and cardiac transplantation for **more than 34 years.**




Dr. Andrew Kao, Medical Director of Heart Transplantation, with the 800th heart transplant recipient, Henry Myers.

ONE PATIENT'S STORY


Several years ago, Ted was a junior at Notre Dame University and a member of the fencing team. He had just returned home to Salina, Kansas, after final exams. Shortly after a hunting trip, he became critically ill and was diagnosed with acute fulminant myocarditis. He was emergently air-lifted to Saint Luke's Mid America Heart Institute. Upon arrival, Ted had a cardiac arrest and required 39 minutes of cardiopulmonary resuscitation (CPR). He first required emergent extracorporeal membrane oxygenation and then biventricular assist devices as a bridge to cardiac transplant. Then, 103 days after he became ill, he received a new heart. Ted made a full recovery and returned to Notre Dame. Almost a year after transplant, he resumed his passion for competitive fencing.



Ted Hodges, 22, competitively fencing at Notre Dame, one year after his heart transplant.



ADVANCED CARDIAC IMAGING



DAVID SKOLNICK, MD
Co-Director, Echocardiography;
Associate Professor of Medicine,
UMKC

ECHOCARDIOGRAPHY

The cornerstone for diagnostic cardiac imaging rests on echocardiography (echo). At Saint Luke's Mid America Heart Institute, the bar for quality is set extraordinarily high. The standards for our echo laboratory do not exist elsewhere within the Midwest. Every physician who interprets echoes has not only passed the initial National Boards of Echocardiography but has also passed the re-certification examination, when eligible. Few centers elsewhere achieve this goal.

We firmly believe that patient care is enhanced when the current echo is compared side-by-side with the previous set of images. No other institution in the region invests this additional time and effort to assess for potential incremental change in left ventricular volume, ejection fraction, myocardial mechanics, diastolic parameters, and severity of valve disease.

As a part of our commitment to education and quality, we host a monthly echo physician meeting to review the updated imaging guidelines and important new research studies. We also lead a weekly teaching conference of echo and multi-modality imaging for our cardiology fellows and faculty colleagues.

In 2018, we performed more than **36,600** echocardiograms including **2,200** transesophageal echocardiograms.



NICHOLAS ORME, MD
Co-Director, Echocardiography;
Assistant Professor of Medicine,
UMKC

CARDIAC COMPUTED TOMOGRAPHY

Our investment in a dual-source, 128-slice cardiac computed tomography (CCT) scanner is another example of our commitment to bring the latest imaging technology to the Kansas City community. This state-of-the-art scanner enables us to obtain extraordinarily accurate diagnostic images with substantially less radiation exposure to the patient. In addition, with less intravenous contrast required for these scans, the risk for contrast-induced kidney injury is significantly reduced.

Commitment to patient safety, the radiation dose is about **90 percent** lower compared to the average CT scanner.



RANDALL THOMPSON, MD
Medical Director,
Cardiac CT Imaging;
Professor of Medicine, UMKC



TIMOTHY BATEMAN, MD
Co-Medical Director,
Cardiovascular Radiologic
Imaging; Professor of Medicine,
UMKC



A. IAIN MCGHIE, MD
Co-Medical Director,
Cardiovascular Radiologic
Imaging; Professor of Medicine,
UMKC

CARDIAC POSITRON EMISSION TOMOGRAPHY

The Cardiovascular Imaging section at Saint Luke's Mid America Heart Institute is nationally renowned for its leadership in stress testing with myocardial perfusion imaging. We have been at the forefront of incorporating cardiac positron emission tomography (PET) into routine clinical practice. One of the first in the nation, we started a cardiac PET program 17 years ago and have additional dedicated PET cameras at three metro-area hospitals. The benefits of this advanced technology include ultra-high-quality images, improved diagnostic accuracy as compared to SPECT studies, quantification of blood flow at rest and stress, and very low doses of radiation. As a result of highly accurate noninvasive scans, the false-positive rate leading to diagnostic angiography is extraordinarily low.

Today, more than 50 percent of the 8,500 myocardial perfusion imaging stress studies performed each year use rubidium-82 PET technology. While not every clinical question requires this form of sophisticated imaging, many of our sicker patients with complex coronary artery disease and heart failure greatly benefit from this imaging technique.

We also routinely use PET with fludeoxyglucose (FDG) to evaluate patients for myocardial viability, and inflammatory cardiomyopathies such as sarcoidosis and infection.



Dr. Timothy Bateman reviewing PET images.



IBRAHIM SAEED, MD
 Medical Director,
 Cardiovascular MRI;
 Associate Professor of Medicine,
 UMKC

CARDIAC MAGNETIC RESONANCE IMAGING


Magnetic resonance imaging (MRI) is an incredibly versatile and powerful tool in cardiovascular medicine. Better imaging enhances our insight and understanding of heart disease. As a result, it improves patient care. For example, cardiac MRI enables us to elucidate the etiology of heart failure. It also serves as a complement to echocardiography for patients with congenital heart disease, intracardiac masses, left ventricular hypertrophy, and ventricular arrhythmias. As a reflection of its integral part in our clinical practice, cardiac MRI volume at Saint Luke’s has more than doubled in the past four years.

Recognizing the growing need for routine MRI studies in patients with pacemakers or implantable cardioverter defibrillators (ICD), Saint Luke’s Mid America Heart Institute pioneered the PROMeNADE registry study (Patient Registry of Magnetic Resonance Imaging in Non-Approved Devices). PROMeNADE, the only program of its kind in the region, has demonstrated MRI safety in this patient population. Since 2015, more than 500 patients have benefited from our research protocol and have undergone a diagnostic MRI.

TAILORED FOR THE PATIENT: THE VALUE OF CARDIAC MRI

Cardiac programs that benefit from MRI

Common indications to improve diagnoses



COMPLEX CORONARY ARTERY DISEASE



J. AARON GRANTHAM, MD
Director, Complex Coronary Interventions; Associate Professor of Medicine, UMKC



ANTHONY HART, MD
Director, Cardiac Intensive Care Unit; Clinical Assistant Professor of Medicine, UMKC



ADAM SALISBURY, MD
ST-Elevation Myocardial Infarction (STEMI) Program Director, Saint Luke's North Hospital; Assistant Professor of Medicine, UMKC

The world's first angioplasty for acute myocardial infarction was performed in 1980 at Saint's Luke's Mid America Heart Institute. That same culture of innovation persists today. The interventional cardiology team at Saint Luke's Mid America Heart Institute continues to pioneer new techniques in the cardiac catheterization lab. The goal of the Complex Higher-Risk Indicated Patients (CHIP) Coronary Intervention Program is to improve the quality of life and the survival of patients with coronary artery disease. Nowhere is the potential to provide benefit greater than among patients with the most complex coronary artery disease, such as those with chronic total occlusions (CTO) and those who are not candidates for surgery. Too often, the culprit vessel is not addressed when it is difficult to treat. Patients are told that nothing can be done, when in fact, complex percutaneous coronary intervention (PCI) could predictably provide benefits.

Perform more than 200 CTO PCI procedures a year, with a success rate greater than 85 percent. One of a few centers in the Midwest that offers this complex level of sophisticated care.

Surgically ineligible patients are those with complex anatomic conditions and multiple co-morbidities. They commonly have CTO, unprotected left main disease, and heavily calcified vessels requiring atherectomy. Few interventional cardiologists are able to successfully overcome these technical challenges. At Saint Luke's, we teach other interventional cardiologists the technique of CTO PCI. Surgical revascularization is not a viable option due to the co-morbidities of diabetes, heart failure, chronic obstructive lung disease, peripheral arterial disease, advanced age, concomitant valvular heart disease, or poor left ventricular function.



Dr. J. Aaron Grantham (third from left) teaches the technique of chronic total occlusion coronary revascularization.

CARDIAC SURGERY



A. MICHAEL BORKON, MD
 Director, Cardiothoracic Surgery; Clinical Professor of Surgery, UMKC



KEITH ALLEN, MD
 Director, Cardiothoracic Surgery Research; Clinical Associate Professor of Surgery, UMKC




ERIC THOMPSON, MD
 Director, Quality, Cardiothoracic Surgery; Clinical Assistant Professor of Surgery, UMKC

A particularly exciting aspect of our cardiothoracic surgery program is its involvement in the National Institutes of Health (NIH) Cardiothoracic Surgical Trials Network (CTSN). The CTSN is a collection of the top cardiothoracic surgery centers in the U.S. and the world, including the University of Southern California, the University of Pennsylvania, the Cleveland Clinic, Dartmouth, and the University of Virginia. Since 2007, the CTSN has conducted numerous leading-edge clinical trials to provide evidence to improve the care and outcomes of patients undergoing cardiac surgery. Recognized as a leader, the surgical team at Saint Luke's joined this prestigious network based on its volumes and quality. Other strengths of our program include excellence in outcomes research and training clinical investigators.

Perform minimally invasive mitral and tricuspid valve surgery

Through its involvement in the CTSN, Saint Luke's Mid America Heart Institute is able to enroll its patients into leading NIH trials. Moreover, the cardiovascular outcomes research group at Saint Luke's contributes to the design of these studies and will offer novel training in implementation science to help train the next generation of academic leaders. As a result, we will continue to improve the care and outcomes of patients requiring cardiac surgery.

Total Coronary Artery Bypass Grafting, Surgical Valve & Other Cardiac Surgery*
 (Hospitals within 1 hr Drive from Saint Luke's)



*De-identified hospitals, based on 2017 HIDI data



Dr. A. Michael Borkon (right) and his team performing coronary artery bypass grafting surgery.

THORACIC SURGERY



JOHN RUSSELL DAVIS, MD
Cardiothoracic Surgeon;
Clinical Associate Professor
of Surgery, UMKC

The thoracic team at Saint Luke’s Mid America Heart Institute emphasizes a multidisciplinary approach, as we care for patients with both benign and malignant masses of the lung, esophagus, chest wall, diaphragm, trachea, and mediastinum. With a single appointment, a patient can be examined by more than one clinical specialist. Our staff includes a thoracic surgeon, interventional general pulmonologist, pulmonologist, radiation oncologist, and medical oncologist. We work side by side in the same clinic setting. With this team of experts, patients are afforded the latest in therapeutic options. More complex medical cases are discussed collectively with input from experts in thoracic radiology and pathology.


Specializing in minimally invasive thoracic surgery, we have built the most active robotic thoracic program in the region. Advanced technology with robotic surgery reduces tissue damage, post-operative pain, and hospital length of stay.

As a result of our robotic thoracic surgical program, patients return to normal activity faster compared to standard open chest surgery. All of these benefits are achieved without compromising the quality of cancer resection. Patients once thought to have no option for a curative resection may be eligible for advanced treatment with radiation, chemotherapy, or immunotherapy, followed by a curative removal of the tumor.



Dr. John Davis specializes in minimally invasive thoracic surgery.

VALVULAR HEART DISEASE



DAVID SKOLNICK, MD
Medical Director, Valve Center;
Associate Professor of Medicine,
UMKC



ADNAN CHHATRIWALLA, MD
Medical Director, Structural
Interventional; Associate
Professor of Medicine, UMKC



A. MICHAEL BORKON, MD
Surgical Director,
Cardiothoracic Surgery;
Clinical Professor of Surgery,
UMKC



KEITH ALLEN, MD
Surgical Director,
Structural Intervention;
Clinical Associate Professor
of Surgery, UMKC

Creating a Valve Center of Excellence at Saint Luke's Mid America Heart Institute embodies our commitment to providing patients access to the full spectrum of high-quality surgical and transcatheter interventions. Life-saving catheter-based intervention has brought new hope to patients who are not ideal candidates for open heart surgery. This innovative technology requires a collaborative approach to patient care and demands further sub-specialization within the fields of cardiac imaging, interventional cardiology, and cardiac surgery. Few hospitals have the depth of resources or the clinical expertise to offer this level of care. Studies in medical literature continue to demonstrate that patient outcomes are better at high-volume institutions. Our team continues to repair and replace more heart valves than any other hospital in the region.

In 2008, our valve team performed the first TAVR in Kansas City and was among the first in the nation. A decade later, we have implanted more than 900 TAVRs.

HIGHLIGHTS OF OUR VALVE CENTER INCLUDE:

- One of 20 centers that participated in the landmark PARTNER trials for transcatheter aortic valve replacement (TAVR), which helped establish TAVR as a new standard of care
- Participated in the landmark COAPT trial, which demonstrated the benefit of the MitraClip™ device in patients with heart failure and functional mitral regurgitation
- A leader in prosthetic valve fracture for valve-in-valve replacement and in alternative access via the transcarotid approach
- One of the few hospitals in the region to offer transcatheter valve-in-valve intervention for degenerative bioprosthetic valves or closure of para-valvular leaks in patients with surgically implanted valves
- With a unique and collaborative partnership with the cardiology team at Children's Mercy Hospital in Kansas City, we provide transcatheter pulmonic valve replacement for adults with complex congenital heart disease

The survival following TAVR at Saint Luke's Mid America Heart Institute is in the top 10 percent in the country.



The multitude of options that Saint Luke's Mid America Heart Institute offers for heart valve disease.

ONE PATIENT'S STORY

Seabrun “Candy” Hunter was a 68-year-old musician who struggled with advanced heart failure due to ischemic heart disease and functional mitral regurgitation. Saint Luke’s Mid America Heart Institute was one of 100 clinical sites in North America that participated in the recently published landmark COAPT trial. This study investigated whether a MitraClip™, a transcatheter mitral valve

repair device, would reduce the risk for heart failure hospitalization and death in patients who were not candidates for surgery. Candy was fortunate to have participated in this study. He has had a profound reduction in the degree of mitral regurgitation and resolution of his shortness of breath.



Seabrun “Candy” Hunter, 68, enjoying life after a life-saving transcatheter mitral valve repair.

ELECTROPHYSIOLOGY



ALAN WIMMER, MD
Medical Director,
Electrophysiology; Associate
Professor of Medicine, UMKC

Experience, volume, and a team-based collaborative approach allow Saint Luke's Mid America Heart Institute to provide high-quality, efficient, and patient-centered care to thousands of patients every year who have heart rhythm disorders. As a result, we are Kansas City's leader in managing atrial fibrillation and complex arrhythmias, like ventricular tachycardia. Our team consists of six board-certified electrophysiologists, five electrophysiology nurse practitioners, and 11 electrophysiology-trained device nurses.

Saint Luke's Mid America Heart Institute is one of only 10 hospitals in the nation that utilizes a 3D mapping system to non-invasively map the source of ventricular tachycardia and atrial fibrillation.

- Our Atrial Fibrillation Clinic provides comprehensive management at all stages of arrhythmia. Special attention to atrial fibrillation begins before diagnosis, identifying patients at risk and providing subsequent intensive risk factor modification.
- We achieve single-procedure freedom from recurrent atrial fibrillation in more than 80 percent of cases.
- We conduct groundbreaking clinical research demonstrating the safety and efficacy of a novel leadless pacemaker and MRI conditional cardiac implantable electronic devices (CIEDs).



Brian M. Ramza, MD, Associate Professor at UMKC, has more than 30 years' experience as a cardiac electrophysiology specialist.

LEFT ATRIAL APPENDAGE CLOSURE: WATCHMAN™ DEVICE



KEN HUBER, MD
Principle Investigator for the two pivotal WATCHMAN™ trials;
Professor of Medicine, UMKC

Anticoagulation comes with risks and challenges. In the absence of appropriate therapy, patients with atrial fibrillation (AFib) are five times more likely to suffer a stroke than those in sinus rhythm. More than 50 percent of these strokes cause severe disability and/or death. While oral anticoagulation is the first-line therapy to reduce the risk of stroke in patients with AFib, a sizable minority of patients have bleeding complications associated with either warfarin or direct oral anticoagulants. Without medication, these patients are unprotected from the risk of stroke. For more than a decade in clinical trials, we have helped pioneer an alternative option for this patient population.

This therapy is called LAA occlusion. The FDA-approved WATCHMAN™ device is a catheter-based mechanical solution to reduce the risk of stroke. The device completely isolates the LAA from the cardiac circulation.

Proud to have implanted
more than **250 devices**
since **2005**.

Since 2005, we participated in the clinical trials (PROTECT AF and PREVAIL) and registries (CAP-1 and CAP-2) that led to the FDA approval of this device in 2015. As a result, we are among the most experienced in the country.



WATCHMAN™ device

ONE PATIENT'S STORY

In 2003, Carl Niederwimmer was admitted to the emergency department for atrial fibrillation. That's when he met Dr. Tracy Stevens, a cardiologist with Saint Luke's Mid America Heart Institute. After treating Carl for many years with systemic anticoagulation, Dr. Stevens encouraged him to consider the WATCHMAN™ device due to his increased risk for bleeding. Carl underwent a catheter-based procedure in early 2016 to put the WATCHMAN™ device inside his heart. It soon

proved to be a smart and crucial decision. One day, Carl was working on his hobby making wooden toys in his shop, which he started long ago to make gifts for his grandkids. He was using a planer and accidentally sliced off the tips of his third and fourth fingers on his left hand.

Although Carl lost the tips to both fingers, it could have been much worse. If Carl had not had the WATCHMAN™ and was still on blood thinners, he would have likely had very serious consequences.



Carl Niederwimmer

PERIPHERAL ARTERIAL DISEASE



KARTHIK VAMANAN, MD
Surgical Director,
Vascular Program

Saint Luke's Mid America Heart Institute offers the Midwest's only multispecialty vascular program. Our integrated vascular program combines the expertise of vascular surgery, vascular medicine, interventional cardiology, and interventional radiology to deliver collaborative, effective, and timely care. Our team participates in national clinical trials focused on improving the treatment of peripheral arterial disease (PAD) and preventing amputation.

Saint Luke's remains the leader in the treatment of PAD within both the Kansas City area and the Midwest. Like other surgical and interventional-based procedures, improved patient outcomes are associated with those institutions with higher case volume. Unique highlights of our PAD program include the following:

- Expertise in health economics research that evaluates new technology to treat vascular disease
- Secured more than \$2 million in funding to study health outcomes in patients with PAD
- Developing an innovative program to deliver high-quality, value-based care to patients with PAD across the health system



MATTHEW BUNTE, MD
Medical Director, Vascular
Program; Assistant Professor
of Medicine, UMKC

CHRONIC VENOUS DISEASE



JASON LINDSEY, MD
Director, Vein Clinic; Assistant
Professor of Medicine, UMKC

Chronic vein disease affects one in three U.S. adults over the age of 65. Since 2010, the Saint Luke's Vein Clinic has provided high-quality treatment to patients suffering the debilitating symptoms of swelling, leg discomfort, and chronic leg ulcers associated with varicose veins and chronic vein disease. Endovascular specialists continue to advance the field of chronic venous occlusive disease, incorporating novel techniques and technologies to provide patients the most contemporary treatment options.

Sometimes the management of acute deep vein thrombus requires the placement of an inferior vena cava (IVC) filter. The removal of chronically placed filters can be challenging. The cardiologists at Saint Luke's Mid America Heart Institute are among the few in Kansas City who have the expertise to safely remove these abandoned filters.

ADULT CONGENITAL HEART DISEASE PROGRAM



ANTHONY MAGALSKI, MD
Medical Director, Adult
Congenital Heart Disease;
Professor of Medicine, UMKC

With the advances in pediatric cardiac surgery decades ago, the number of adults with congenital heart disease (CHD) now surpasses the number of children with this condition. As a result, 90 percent of children born with CHD survive to adulthood, and there are more than one million adults with CHD in the United States. To address the urgent and unmet needs of this diverse patient population, the physicians at Saint Luke's Mid America Heart Institute have worked closely with both the cardiology and cardiac surgical teams at Children's Mercy Hospital of Kansas City for nearly 20 years to build a successful adult CHD program. Recently, the American College of Cardiology and Adult Congenital Heart Association urged adult CHD patients to be regularly evaluated at specialized adult CHD centers, like the one at Saint Luke's Hospital. Our program offers:

- City-wide congenital conferences
- More than 1,500 outpatient visits each year
- More than 100 adult congenital heart cardiology procedures and operations each year
- Genetic counseling
- High-risk pregnancy care for those with adult CHD or heart disease with pregnancy



Andrew Widman was born with congenital heart disease, but because of a heart transplant he can now do things he's never done before.

HEART DISEASE IN PREGNANCY PROGRAM



LAURA SCHMIDT, MD
Co-Medical Director,
Heart Disease in Pregnancy
Program; Clinical Assistant
Professor of Medicine, UMKC



KAREN FLORIO, DO
Co-Medical Director,
Heart Disease in Pregnancy
Program

For pregnant women with acquired or adult congenital heart disease, some conditions can place the mother and/or the fetus at a high risk for serious complications. As a commitment to our community, Saint Luke's Mid America Heart Institute created a Heart Disease in Pregnancy Program, the first in the country. Last year we cared for more than 250 patients. The program represents a collaborative effort between two groups of highly trained teams sub-specializing in adult congenital heart disease and maternal fetal medicine. If necessary, labor and delivery takes place in the cardiovascular intensive care unit and cardiac operating room, respectively. We offer:

- Geneticists for both maternal and fetal testing
- Pediatric cardiology to evaluate fetal hearts for potential abnormalities

ONE PATIENT'S STORY

Mindy Corbin required her first heart transplant shortly after high school. Eight years later, she required a second transplant. After getting married, her cardiologist in California cautioned her that pregnancy could be life-threatening. When she moved back to the Kansas City area, she sought a second opinion at Saint Luke's Mid America Heart Institute. With the support and guidance of our Heart Disease in Pregnancy Program, Mindy was safely able to deliver Mikayla in 2013 and Madelyn in 2017.



Mindy Corbin, two-time heart transplant recipient, becomes a mother of two.

CARDIAC AMYLOID CLINIC



IBRAHIM SAEED, MD
Co-Medical Director,
Cardiac Amyloid; Associate
Professor of Medicine, UMKC



BRETT SPERRY, MD
Co-Medical Director,
Cardiac Amyloid; Assistant
Professor of Medicine, UMKC


Cardiac amyloid is no longer considered a rare disease and is a potential cause for diastolic heart failure (HF). More importantly, we have new therapies to treat this form of HF. Our comprehensive team diagnoses and treats patients with all forms of amyloidosis, and is comprised of cardiologists, hematologists, nephrologists, and neurologists. Saint Luke's Mid America Heart Institute has advanced imaging techniques to make a non-invasive diagnosis of cardiac amyloidosis such as cardiac MRI, echocardiography with longitudinal strain, and technetium pyrophosphate scintigraphy. We have published extensively in this field and participate in national clinical trials with novel therapeutic agents.

A rapid diagnosis is key, and new treatment options and clinical trials are available to many of our patients.


We are proud to be the first recognized amyloidosis treatment center in the region with three certifications:

- Amyloidosis Research Consortium
- Amyloidosis Patient Support Group
- Amyloidosis Foundation

ONLY AMYLOID CLINIC IN 5-STATE REGION







PREVENTION

MURIEL I. KAUFFMAN WOMEN'S HEART CENTER



TRACY STEVENS, MD
Medical Director,
Muriel I. Kauffman
Women's Heart Center;
Professor of Medicine, UMKC



MARCIA MCCOY, RN, MSN
Director, Muriel I. Kauffman
Women's Heart Center

Saint Luke's Muriel I. Kauffman Women's Heart Center is nationally recognized for its commitment to women's heart health. As the first center of its kind in the United States, the Women's Heart Center focuses on proactive education and awareness of the unique gender-related characteristics ranging from risk factors to symptoms to clinical presentation. The Women's Heart Center team is dedicated to research and provides educational opportunities for community and business organizations. Celebrating its twenty-fifth anniversary, the Women's Heart Center has expanded to focus on the heart health of the entire family.

- Recognized at two White House receptions for its pioneering efforts in women's heart health
- Dr. Tracy Stevens serves as a national spokesperson for the America Heart Association
- Founding partner of the National Heart, Lung, and Blood Institute's Heart Truth Campaign, a national lifesaving campaign that has effectively raised awareness of cardiovascular disease in women
- Founding Alliance Member with WomenHeart: The National Coalition for Women with Heart Disease
- Food as Medicine Institute founding Alliance Member



Marcia McCoy, Julia Irene Kauffman, Laura Bush, former First Lady, and Dr. Tracy Stevens

CHARLES & BARBARA DUBOC CARDIO HEALTH & WELLNESS CENTER




JAMES O'KEEFE, MD
Medical Director,
Cardio Health & Wellness Center;
Professor of Medicine, UMKC

Saint Luke's Charles & Barbara Duboc Cardio Health and Wellness Center is committed to controlling cardiovascular risk factors to help ensure that patients can lead long and healthy lives. The Cardio Health and Wellness Center exceeds national benchmarks for risk factor modification, with potentially lifesaving results. While 80 percent of patients followed in the Center have known heart disease, fewer than 1 percent had a cardiac event in the past year. Our program manages hypertension, cholesterol, diabetes, sleep apnea, atrial fibrillation, tobacco abuse, fatty liver disease, vascular disease, heart disease, stroke prevention, obesity, and nutrition.

While 80 percent of patients followed in the Center have known heart disease, **fewer than one percent** had a cardiac event in the past year.

- Multidisciplinary team of cardiologists, nurse practitioners, and nurses work closely to care for more than 6,000 patients annually
- Only 2 percent of patients remain smokers
- Pioneers of a CardioScan program that is affordable and patient-friendly, allowing the general population unprecedented access to the status of their coronary artery disease burden



MICHAEL & MARLYS HAVERTY CARDIO METABOLIC CENTER OF EXCELLENCE



MIKHAIL KOSIBOROD, MD
Co-Director, Harverty Cardio
Metabolic Center of Excellence;
Professor of Medicine, UMKC



JAMES O'KEEFE, MD
Co-Director, Harverty Cardio
Metabolic Center of Excellence;
Professor of Medicine, UMKC

The Cardio Metabolic Center of Excellence was launched in 2019 to improve the outcomes of people with diabetes and pre-diabetes, which now affect one-third of all American adults. Patients with Type 2 diabetes and established cardiovascular disease represent one of the highest risk groups and are responsible for a large proportion of hospital admissions and health care costs.

The management of this patient group is growing increasingly complex, due to a heavy burden of vascular complications, comorbid conditions, and the emergence of many novel therapeutic options. New medicines developed for glucose lowering have demonstrated cardiovascular benefits. These agents also target and reduce inflammation. Management of these patients requires coordinated care by a multidisciplinary team, which is difficult to deliver in the typical fragmented American health care model with limited time allotment for chronic disease management. Health care delivery is shifting from volume-based to value-based care models. Our new clinic is designed to reduce the morbidity of cardiovascular events in patients with diabetes and pre-diabetes.

Diabetes and Risk of Heart Disease



Adults with diabetes are two to four times more likely to have heart-related complications.

ATHLETIC HEART CLINIC



ANTHONY MAGALSKI, MD
Director, Athletic Heart Clinic;
Professor of Medicine, UMKC

The risk of sudden cardiac death in young, competitive athletes has raised the awareness of potential heart disease in this unique population. Nearly one percent of all athletes screened are found to have an undiagnosed cardiac condition, placing them at potential risk for sudden cardiac death. In 2009, the Athletic Heart Clinic extended this important screening process to middle and high school athletes throughout the region.

- Recognized leaders in the field of sports cardiology
- Only such program in the region
- Screened more than 3,000 National Football League draft combine players

Since 2004, Saint Luke's Athletic Heart Clinic has collaborated with a major regional university to ensure that its athletes are "safe to play."


ONE PATIENT'S STORY

Samsson Destahun played tennis for his high school team and was an avid runner. Until evaluated at Saint Luke's Athletic Heart Clinic, he thought it was normal to have bouts of sustained tachycardia. At age 17, his screening ECG helped confirm the diagnosis of Wolff-Parkinson-White syndrome. His arrhythmia is now cured, following an electrophysiology study and ablation.



Samsson Destahun is living life to the fullest.





CARDIOVASCULAR RESEARCH

OUTCOMES RESEARCH

Medicine is facing an unparalleled demand for leaders capable of defining and quantifying patient outcomes, comparing the effectiveness of alternative treatments, and translating new knowledge into clinical care. Programs dedicated to outcomes and quality of care research help meet the growing national demand for scholars with these specialized research capabilities. Among the best measures of success for Saint Luke's Mid America

Heart Institute's outcomes research program are the quantity and quality of published peer-reviewed scientific papers.

Our researchers have published more than 1,000 peer-reviewed scientific papers in the past five years. These articles have been published in many of the highest impact medical journals including *The New England Journal of Medicine*, *Journal of American Medical Association (JAMA)*, *The Lancet*, *Circulation*, and the *Journal of the American College of Cardiology*.

Much of our research funding comes from the National Institutes of Health, the federally funded Patient-Centered Outcomes Research Institute, the American Heart Association, and the American College of Cardiology.

Alongside centers from Harvard, Yale, and Duke, Saint Luke's Mid America Heart Institute serves as one of four designated data analytic centers for the American College of Cardiology's National Cardiovascular Data Registry.

\$7.5 MILLION
IN RESEARCH FUNDING IN 2018

THE WORLD'S MOST INFLUENTIAL SCIENTIFIC MIND

Saint Luke's Mid America Heart Institute researcher John A. Spertus, MD, MPH, is one of the *Most Influential Scientific Minds* in clinical medicine in 2017, according to Clarivate Analytics, a global leader that focuses on the analytics of scientific and academic research. Studies published by Dr. Spertus are consistently deemed significant by his peers, placing him in the top one percent of authors cited in research. He was also named among the *World's Most Influential Scientific Minds of 2014* by Thomson-Reuters.

Dr. Spertus is the Director of Outcomes Research at Saint Luke's Mid America Heart Institute and the Lauer Missouri Endowed Chair and Professor of Medicine at the University of Missouri-Kansas City. His research focuses on personalized medicine, measuring outcomes and health care quality, and the use of information technology to guide medical decision making. Dr. Spertus received the American Heart Association's (AHA) *Quality of Care and Outcomes Research Outstanding Lifetime Achievement Award* in 2015, and has been recognized by the AHA as a Distinguished Scientist in 2018 for research that has advanced the understanding of cardiovascular disease and stroke.




John A. Spertus, MD, MPH, Professor of Medicine, UMKC

DIABETES RESEARCH—THE LINK TO IMPROVED HEART HEALTH

Cardiometabolic disease, which includes diabetes, pre-diabetes, obesity, and insulin resistance, is becoming the world’s leading cause of non-communicable disorders and is increasing in epidemic proportions. Under the direction of Mikhail Kosiborod, MD, the Cardio-Metabolic Research Group has emerged as a national and international leader in the field of cardio-metabolic disorders. This group also serves as a data analytic center for large registries of patients with diabetes in the United States and around the globe. Their work includes the American College of Cardiology–directed Diabetes Collaborative Registry, which is rapidly becoming the largest diabetes registry in the United States. Many of the leading clinical trials are coordinated and directed by Saint Luke’s Mid America Heart Institute.




Mikhail Kosiborod, MD, Vice President of Research, Saint Luke’s Health System; Professor of Medicine, UMKC



EDUCATION AND FELLOWSHIP TRAINING PROGRAMS

CARDIOVASCULAR DISEASE FELLOWSHIP



JONATHAN ENRIQUEZ, MD
Program Director,
Cardiovascular Fellowship;
Associate Professor of Medicine,
UMKC

The Cardiovascular Disease Fellowship Program, jointly offered by Saint Luke’s Mid America Heart Institute and the University of Missouri–Kansas City School of Medicine, offers an accredited three-year training program for a total of 12 general cardiology fellows. Our highly competitive general cardiology training program receives nearly 500 applications each year for four positions.

Dedication to the academic missions of education and research focuses and engages our faculty in the latest developments in cardiovascular medicine. As a result, patient care continues to improve.



David Skolnick, MD, Cardiologist, rounding with residents.

Further subspecialization training is available in the following fields:

Interventional Cardiology

- One of the premier interventional cardiology training programs in the United States
- Established in 1987 by Geoffrey Hartzler, MD, the program receives more than 100 applications per year for two positions

Structural Intervention Fellowship

- Established in 2016, it provides advanced training in transcatheter aortic and pulmonary valve replacement, transcatheter mitral valve repair, left atrial appendage occlusion, atrial septal defect, and patent foramen ovale closure

CHIP/CTO Fellowship

- Established in 2018 under the direction of J. Aaron Grantham, MD, this program provides advanced training in Complex Higher-Risk Indicated Patients (CHIP) and Chronic Total Occlusions (CTOs)

Advanced Heart Failure and Transplant

- Kansas City's first and only Accreditation Council of Graduate Medical Education (ACGME)-accredited fellowship program for advanced heart failure and transplant
- Established in 2012 and among the first in the United States to receive this designation

Clinical Cardiac Electrophysiology

- A two-year program offering a wide variety and high volume of procedures, including complex ablations and device implantation

Nuclear Cardiology and Echocardiography

- One-year advanced imaging fellowships in nuclear cardiology and echocardiography are available for cardiologists interested in this additional training

Cardiovascular Outcomes Research

- Funded by a T-32 grant from the National Institutes of Health
- Designed to train physician-scientists to pursue a career in academic cardiology

EDUCATING KANSAS CITY FOR 49 YEARS: DR. ROBERT D. CONN HEART CONFERENCE


Our Annual Heart Conference, established in 1970, reflects our dedication to raise the standard of cardiovascular care through education within our community and the surrounding region. The conference is a two-day accredited meeting, sponsored by Saint Luke’s Mid America Heart Institute. In recognition of our commitment to education, the Missouri Chapter of the American College of Cardiology partners with our conference. We are a well-established regional meeting, with more than 200 physicians, nurse practitioners, and nurses attending each year.



Missouri
CHAPTER



2018 Dr. Robert D. Conn Heart Conference in Kansas City, Missouri



MEET THE TEAM

SAINT LUKE'S CARDIOVASCULAR CONSULTANTS

CARDIOLOGISTS




Suzanne Arnold, MD



Bethany Austin, MD



Dmitri Baklanov, MD



Charles Barth III, MD



Timothy Bateman, MD



Matthew Bunte, MD



Kevin Bybee, MD



Paul Chan, MD




Adnan Chhatriwalla, MD



Matthew Deedy, MD



Michelle Dew, MD



Jonathan Enriquez, MD



Mark Everley, MD



Timothy Fendler, MD



Adam Fleddermann, MD



Michael Giocondo, MD




Joseph Goeke, IV, MD



Thomas Good, MD



Garth Graham, MD




J. Aaron Grantham, MD



Anna Grodzinsky, MD



Sanjaya Gupta, MD



Anthony Hart, MD



Kenneth Huber, MD



Dany Jacob, MD



Andrew Kao, MD



Taiyeb Khumri, MD



Mikhail Kosiborod, MD



Steven Laster, MD



Stephanie Lawhorn, MD



John Kenneth Lee, MD



Jason Lindsey, MD




Anthony Magalski, MD



Michael Main, MD



Susan Mayer, MD



Justin McCrary, MD



A. Iain McGhie, MD



Michael Nassif, MD



James O'Keefe, MD



Nicholas Orme, MD



John Peterson, MD



Riaz Rabbani, MD



Valerie Rader, MD



Brian Ramza, MD



Carlos Rivas-Gotz, MD

CARDIOLOGISTS, continued



Barry Rutherford, MD



Ibrahim Saeed, MD



David Safley, MD



Mohammed Saghir, MD



Adam Salisbury, MD




John Saxon, MD



Laura Schmidt, MD



James Sear, MD



David Skolnick, MD



Brett Sperry, MD



Daniel Steinhaus, MD



Tracy Stevens, MD



Robert Tanenbaum, MD



Randall Thompson, MD



Deepa Upadhyaya, MD



Deepthi Vodnala, MD



Alan Wimmer, MD



Omair Yousuf, MD



Martin (Tony) Zink, III, MD

CARDIOLOGY ADVANCED PRACTICE PROVIDERS



Laura Amos



Megan Arnone



Kayla Barta



Kimberly Berthold



Tara Brand-Moody



Julia Bridges



Sarah Brown



Erin Broxterman



Kim Buehler



Kristina Calkins



Kimberly Campbell



Alicia Clark



Faith Cordle



Diane Cunningham




Kasey Dunn



Catherine Friends



Utaiwan (Tai) Greer



Nicole Hoover



Katie Jaschke



Lisa Jennings



Sophia Kats



Lisa Kennedy



Lyndsay Kidd



Erin Kreisel



Barbara Lee

CARDIOLOGY ADVANCED PRACTICE PROVIDERS, continued



Janet Lipke



Jessica Love



Kelsey Megaris



Rane Mehta



Terri Meyer



Tiffany Meyers



Melissa Murphy



Angela Postma



Lauren Rasmussen



Betsey Rohr



Kristine Rottinghaus



Serkalem Sisay



Sarah Smith



Amy Stark



Patricia Walsh



LeAndrea Williams



Carol Wood

MID AMERICA HEART AND LUNG SURGEONS

CARDIOTHORACIC SURGEONS



Sanjeev Aggarwal, MD



Keith Allen, MD



A. Michael Borkon, MD



John Russell Davis, MD



Jessica Heimes, DO



Graham Pollock, MD



Van Eric Thompson, MD

VASCULAR SURGEONS



Samantha Alsop, MD



Karthik Vamanan, MD

CARDIOTHORACIC ADVANCED PRACTICE PROVIDERS



Meredith Annin



Alyson Clark



Mary Cummings



Patrick Egger



Courtney Eklund



Paul Jenkins



Julie Jennings



Kristen Kumar



Laura Langmack



Chao Li



Chelsea Light



Annamarie Mandacina



Mark Mann



Briana McKiddy



Lauren Ori



Joy Rodenberger



Megan Shah



Alyson Spiek



Laura Stockamp



Justine Uryasz



Morgan Walker



Dianna Williams



Rachel Zimmerman

SAINT LUKE'S ANESTHESIOLOGY

ANESTHESIOLOGISTS



Robert Covington, DO



Jim Kelly, Jr., MD




Brad Kelsheimer, MD



Matt Waldron, MD



Campbell Williams, MD



C. Mark Williams, MD

CRITICAL CARE TRAINED ANESTHESIA



Michelle Haines, MD



Jon Kozinn, MD



Venkat Mangunta, MD



Larisa Zhurav, MD

CRITICAL CARE TRAINED INTENSIVIST



Thomas Cooper, MD



Carole Freiberger-O'Keefe, DO



Andrew Schlachter, MD

CRITICAL CARE ADVANCED PRACTICE PROVIDERS



Jessica Begley



Heather Boyd



Bethany Brown



KaLee Dahmer



Rachel Derenski



Shane Hagen



April Jennings



Jessica Koprivica



Shannon Lynn



Fallon Perry



Abigail Poindexter



Holly Smith



Shalan Stroud




Stephanie Woodke



Morgan Woolsey

Not pictured:
Nathan Hagen



**WITH HEARTFELT
GRATITUDE**

THANK YOU TO OUR DONORS

The philanthropic support from our community has an immediate and lasting impact on our ability to serve as one of the nation's leading heart hospitals. The generosity and vision of our donors enable us to launch nationally recognized programs, to purchase leading-edge medical technology and to enhance our commitment to education and research. Combined, these efforts contribute to our cardiovascular knowledge and ability to improve patient care. On behalf of our patients and their families, we are honored and thankful for your financial support.

LEADERSHIP DONORS

Marilyn L. Altenderfer
Satish C. Bansal, MD, and Roopa Bansal, MD
Melinda and Tom Beal
Edna Bear
Beta Sigma Phi Endowment Fund
Jim Binney
Blue Cross and Blue Shield of Kansas City
William and Mary Shaw Branton
Gene and Joanne Cable
David F. Cahill
Kay, John, and Mark Callison
Edith and Harry Darby Foundation
Elizabeth Davis
DST Systems, Inc.
Charles A. Duboc, PhD, and Barbara D. Duboc
Doris Duke Charitable Foundation
J. E. Dunn Construction Company
Robert G. and Marie E. Evans
Louis L. Flarsheim
Emmagene C. Fleming Trust
Fred D. Fowler, MD
David and Lorelei Gibson
William Noland Gillmor Trust
Mary Katherine Goldsmith Trust
Arvin Gottlieb Charitable Foundation
Bill and Mary Grant
Hall Family Foundation
Geoffrey O. Hartzler, MD, and Dorothy E. Hartzler
Michael and Marlys Haverty
Charles and Mary Kay Horner
Margot and Allan Huber
Larry and Sara Lynn Jones
Julia I. Kauffman
Muriel McBrien Kauffman Foundation
James M. Kemper Jr.
William T. Kemper Foundation, Commerce Bank, Trustee
Kids Classic Fund
Warner Lambert Company
Jim and Lois Lacy
Miller Nichols Charitable Foundation
MRIGlobal
Leila E. Normandie
Elliot and Helena Norquist
Kevin K. Nunnink Foundation
I. A. O'Shaughnessy Foundation
Shaw Electric Company
The Sunderland Foundation
James P. Pace Family Foundation
Craig and Anne Patterson
Peggy A. Randall
Barbara and Ed Roberts
Morton and Estelle Sosland
Sosland Foundation
Victor E. Speas Foundation, Bank of America, Trustee
Frank L. and Evangeline A. Thompson
Edwin and Mariel Thompson
Courtney S. Turner Charitable Trust/
Daniel C. Weary & Bank of America Trustees
Robert W. and Katherine H. Wagstaff
Robert and Marcia Wolff
David Woods Kemper Foundation
John R. Zajic

Leadership donors are benefactors who have given a lifetime cumulative gift of \$100,000 or more.

The following projects and programs benefit from the generosity of our donors.

CENTERS, PROGRAMS, & INITIATIVES

3D imaging for Electrophysiology research
Advanced Cardiology Fellowships
Arvin Gottlieb Heart Failure & Transplant Center
Athletic Heart Clinic
Ben McCallister Clinical Scholars Program
Michael & Marlys Haverty Family Cardio Metabolic Program
Cardiovascular Grand Rounds
Charles & Barbara Duboc Cardio Wellness Center
Courtney S. Turner Charitable Trust, Daniel C. Weary & Bank of America Trustees Patient Care Center
Frank L. and Evangeline A. Thompson Cardiovascular Interventional & Surgical Center
Hartzler Conference Room for continuing medical education
Heart Disease and Pregnancy Program
Imaging Core Laboratory
International mummy research to assess dietary and environmental impact on coronary atherosclerosis
James P. Pace Family Foundation Patient & Family Welcome Center
Kevin K. Nunnink ECMO Program
Muriel I. Kauffman Women's Heart Center
Nationally recognized Food as Medicine Everyday and CDC Million Hearts Initiative
Nursing scholarships for continuing education
Patient Financial Assistance
The Patient Registry of Magnetic Resonance Imaging in Non-Approved Devices (PROMeNADE)
Preventative, *From the Heart*, newsletter to the community
Dr. Robert D. Conn Heart Conference
The Sunderland Foundation Patient Care Center
Valve Center of Excellence
William T. Kemper Foundation Patient Care Center

ENDOWED RESEARCH CHAIRS

- A. Michael Borkon, MD, Frank L. and Evangeline A. Thompson Endowed Chair in Cardiovascular Surgery and Transplantation
- Anthony Magalski, MD, Arvin Gottlieb Endowed Chair in Heart Failure
- Brian M. Ramza, MD, PhD, Frank L. and Evangeline A. Thompson Endowed Chair in Electrophysiology Research
- John A. Spertus, MD, Daniel J. Lauer, MD, Missouri Endowed Chair in Metabolism and Vascular Research
- Tracy L. Stevens, MD, FACC, Julia Irene Kauffman Endowed Chair in Women's Cardiovascular Health

LOCATIONS

Saint Luke's Hospital of Kansas City

Kansas City, MO

Saint Luke's East Hospital

Lee's Summit, MO

Saint Luke's North Hospital–Barry Road

Kansas City, MO

Saint Luke's South Hospital

Overland Park, KS

Saint Luke's Cushing Hospital

Leavenworth, KS

Anderson County Hospital

Garnett, KS

Hedrick Medical Center

Chillicothe, MO

Wright Memorial Hospital

Trenton, MO

Saint Luke's Multispecialty Clinic–Blue Springs

Blue Springs, MO

Saint Luke's Multispecialty Clinic–Mission Farms

Overland Park, KS

Saint Luke's Transplant Clinic–Wichita

Wichita, KS

Saint Luke's Transplant Program–Joplin

Joplin, MO

Saint Luke's Cardiovascular Consultants

Outreach Clinic
Clinton, MO
Warrensburg, MO

Saint Luke's Community Hospitals

A division of Saint Luke's South Hospital
Kansas City, KS
Leawood, KS
Olathe, KS
Overland Park, KS
Roeland Park, KS
Shawnee, KS
Overland Park (South), KS



saintlukeskc.org/heart

816-931-1883



4401 Wornall Road
Kansas City, MO 64111
816-932-2000
saintlukeskc.org/heart